Low Neurophysiologic Resistance to Anesthetics as a Marker of Preclinical/Prodromal Alzheimer's Disease and Neurovascular Pathology, Delirium risk and Inattention

摘要 在母公司R01的研究项目中，题为“麻醉药的低神经生理抵抗作为 临床前/先兆阿尔茨海默病和神经血管病理学、妄想症风险和注意力不集中 脑内神经退行性疾病类型改变的检查 结构和活性，使患者容易表现出对麻醉药反应的脑活动变化 在手术期间提供的。这个R01项目利用了麻醉剂改变大脑活动的想法 药物反映了不健康的大脑，可能有临床前AD的潜在迹象，可能表明 患POD的风险增加。R01项目的预期结果是更好地了解机制 麻醉药物、术后妄想、阿尔茨海默病、S病的潜在术中脑电反应 和相关的痴呆，以及这些实体之间的关系。 在这项行政补充申请中，我们建议调查临床前/ 前驱路易体痴呆(LBD)病理(即一种名为α-突触核蛋白的蛋白质的改变形式) 。众所周知，精神错乱和精神错乱的患者 痴呆症患者在前α/θ频率和总体主导频率上表现出类似的脑电异常， 与LBD患者相似。因此，麻醉期间的脑电活动模式可能能够作为一种 指标-突触核蛋白水平，这可能有助于识别高危患者，以便进一步检查LBD，AD， 和其他相关的痴呆症2-4

SUMMARY In the parent R01 research project entitled "Low Neurophysiologic Resistance to Anesthetics as a Marker of Preclinical/Prodromal Alzheimer's Disease and Neurovascular Pathology, Delirium risk and Inattention," we are examining whether - neurodegenerative disease-type changes in brain structure and activity, predispose patients to show altered brain activity changes in response to anesthetic drugs provided during surgery. This R01 project exploits the idea that altered brain activity in response to anesthetic drugs reflects an unhealthy brain, which may have latent signs of pre-clinical AD and which may indicate an increased risk of POD. The expected outcome of the R01 project is to understand better the mechanisms underlying intraoperative brain EEG responses to anesthetic drugs, postoperative delirium, Alzheimer s Disease and related dementias, and relationships between these entities. In this Administrative Supplement application, we propose to investigate the relationship between preclinical/ prodromal Lewy body dementia (LBD) pathology (ie altered forms of a protein called alpha synuclein) . It has been well established that patients with delirium and dementia display similar EEG abnormalities in pre-alpha/theta frequencies and dominant frequency overall, similar to patients with LBD. Thus, EEG activity patterns during anesthesia may be able to serve as an indicator -Synuclein levels, which might help to identify at risk patients for further workup for LBD, AD, and other related dementias.2-4